Related Experiment Videos
Leukocytapheresis therapy for severe ulcerative colitis.
M Sasaki1, T Tsujikawa, Y Fujiyama
1Second Department of Internal Medicine, Shiga University of Medical Science, Japan.
Summary
Leukocytapheresis (LCAP) therapy shows promise for severe ulcerative colitis attacks, even when glucocorticoids fail. This treatment improved outcomes in most patients, offering a potential alternative for refractory cases.
Area of Science:
- Gastroenterology
- Immunology
Background:
- Severe ulcerative colitis attacks necessitate prompt intervention, often involving glucocorticoids.
- Surgical intervention is considered for glucocorticoid-refractory cases.
Observation:
- An open clinical study investigated leukocytapheresis (LCAP) for severe ulcerative colitis.
- Nine patients with severe ulcerative colitis, seven refractory to intravenous glucocorticoids, were enrolled.
Findings:
- LCAP was administered weekly for 4-5 weeks using a leukocyte apheresis filter.
- Six out of nine patients demonstrated overall improvement post-LCAP therapy.
- Three patients achieved remission, indicating significant therapeutic benefit.
Implications:
- LCAP therapy presents a viable treatment option for severe ulcerative colitis, particularly in glucocorticoid-intolerant or non-responsive patients.
- Further research into immunological markers may elucidate LCAP's precise mechanisms of action.